

Aktuelle Konzepte der palliativen Systemtherapie bei Urothelkarzinomen

Günter Niegisch

Literatur

1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D. K., AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0. 2020 (abgerufen Mai 2021) (<http://leitlinienprogramm-onkologie.de/Harnblasenkarzinom.92.0.html>).
2. Necchi A, et al. Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. *Clin Genitourin Cancer*, 2015. 13: 178–184.
3. Locke JA, et al. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. *Clin Genitourin Cancer*, 2016. 14: 331–340.
4. von der Maase H, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol*, 2000. 18: 3068–3077.
5. Sternberg CN, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. *J Clin Oncol*, 2001. 19: 2638–46.
6. Galsky MD, et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. *J Clin Oncol*, 2011. 29: 2432–2438.
7. Dash A, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. *Cancer*, 2006. 107: 506–513.
8. Balducci L, Yates J General guidelines for the management of older patients with cancer. *Oncology (Williston Park)*, 2000. 14: 221–27.
9. De Santis M et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. *J Clin Oncol*, 2012. 30: 191–199.
10. Culine S et al. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). *Eur Urol*, 2011. 60: 1251–1257.
11. Balar AV et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet*, 2017. 389: 67–76.
12. Balar AV, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. *Lancet Oncol*, 2017. 18: 1483–1492.

13. EMA. Pressemitteilung. EMA restricts use of Keytruda and Tecentriq in bladder cancer. <https://www.ema.europa.eu/en/news/ema-restricts-use-keytruda-tecentriq-bladder-cancer>.
14. Powles T, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med*, 2020. 383: 1218–1230.
15. Alva A, et al. LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. *Ann Oncol*, 2020. 31(S1155).
16. Powles T, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*, 2020. 21: 1574–1588.
17. Galsky MD, et al., Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet*, 2020. 395: 1547–1557.
18. Bellmunt J, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N Engl J Med*, 2017. 376: 1015–1026.
19. Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet*, 2016. 387: 1909–1920.
20. Sharma P, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*, 2017. 18: 312–322.
21. Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*, 2018. 391: 748–757.
22. Szabados B, et al. Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. *Eur Urol*, 2018. 73(2): p. 149-152.
23. Gomez de Liano Lista A, et al. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. *Eur Urol*, 2020. 77: 269–276.
24. Bellmunt J, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. *J Clin Oncol*, 2009. 27: 4454–4461.
25. Powles T, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *N Engl J Med*, 2021. 384: 1125–1135.
26. Loriot Y, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med*, 2019. 381: 338–348.